Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDF190400338
- Development stage
- Preclinical
- Lead developer
- IlDong Pharmaceutical Co Ltd
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
IDF190400338 is a small-molecule dual modulator of the adenosine A1 and A2A receptors being developed by Ildong Pharmaceutical and its R&D subsidiary, Yunovia, for the treatment of Parkinson's disease. Adenosine receptors are integral to the modulation of dopaminergic signaling within the basal ganglia, a key area affected in Parkinson's disease. By targeting both the A1 and A2A receptor subtypes, the compound aims to improve motor function and potentially offer neuroprotective effects. The drug is currently in the preclinical stage, specifically undergoing IND-enabling studies to support future clinical trials.
- Other names
- Ildong A1/A2A receptor modulator
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)
Beyond the preview
Go deeper on IDF190400338.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDF190400338.